Quidel Stock

Quidel ROE

The Return on Equity (ROE) of Quidel (QDEL) as of Aug 10, 2026 is -58.93 %. In the previous year, Return on Equity (ROE) was -68.76 % — a change of -14.29% (higher).

ROE

-58.93 %

YoY

-14.29%

Last updated:

In 2026, Quidel's return on equity (ROE) was -58.93 %, a -14.29% increase from the -68.76 % ROE in the previous year.

Access this data via the Eulerpool API

Quidel Stock analysis

What does Quidel do? Quidel Corporation is a US-based company specializing in the production of rapid tests for medical diagnostics. It was founded in 1979 and is headquartered in San Diego, California. Since 1991, it has been listed on the NASDAQ stock exchange. Quidel initially started as Diagnostic Reagents Laboratory (DRL) and focused on manufacturing diagnostic products for the veterinary sector. In 1990, it was renamed Quidel Corporation and expanded its operations into human diagnostics. The company's business model revolves around the development and production of immunological rapid tests that can quickly and easily diagnose infectious diseases and other health problems. Quidel focuses on creating high-quality, accurate, and cost-effective test procedures that can be used by healthcare professionals or even laypersons at home. One of Quidel's core competencies is bringing to market rapid tests that are easy to perform and provide immediate results without the need to send samples to a laboratory. The company offers a wide range of rapid tests for diagnosing various diseases. These include tests for infectious diseases such as influenza, streptococcus, Lyme disease, and chlamydia, as well as tests for pregnancy, drug abuse, and cardiovascular diseases. The tests are available as single tests or panel tests that can diagnose multiple diseases simultaneously. Quidel operates in four business segments: Molecular Diagnostics, Point-of-Care Diagnostics, Immunoassays, and Specialized Diagnostic Solutions. The Molecular Diagnostics segment focuses on developing molecular diagnostic tests and instruments for laboratory use. The Point-of-Care Diagnostics segment develops and produces rapid tests for use in medical practices and hospitals. The Immunoassays segment specializes in reagent-based tests for the quantitative analysis of biomolecules. The Specialized Diagnostic Solutions segment includes specialized diagnostic products, such as test systems for monitoring antibiotic therapies. In conclusion, Quidel Corporation specializes in the development and production of rapid tests for medical diagnostics. The company offers a wide range of high-quality, accurate, and cost-effective test procedures for diagnosing infectious diseases, pregnancy, drug abuse, and cardiovascular diseases. Quidel has gained a significant market share in the diagnostics field through its rapid tests and diverse range of test panels for various conditions, and it is known for its innovative products. Quidel is one of the most popular companies on Eulerpool.

ROE Details

Decoding Quidel's Return on Equity (ROE)

Quidel's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Quidel's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Quidel's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Quidel’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Quidel stock

Return on Equity (ROE) of Quidel is -58.93 % in 2026.

Return on Equity (ROE) of Quidel changed from -68.76 % to -58.93 %, representing a -14.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Quidel since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Quidel with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Quidel

All Key Metrics — Quidel